nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—ERBB3—chronic obstructive pulmonary disease	0.382	0.665	CbGaD
Dasatinib—CYP1A1—chronic obstructive pulmonary disease	0.098	0.171	CbGaD
Dasatinib—CYP1A2—chronic obstructive pulmonary disease	0.0945	0.165	CbGaD
Dasatinib—FMO3—sweat—chronic obstructive pulmonary disease	0.00779	0.0713	CbGeAlD
Dasatinib—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.00682	0.209	CbGbCtD
Dasatinib—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.00555	0.17	CbGbCtD
Dasatinib—EPHA2—pulmonary artery—chronic obstructive pulmonary disease	0.00402	0.0368	CbGeAlD
Dasatinib—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.00375	0.115	CbGbCtD
Dasatinib—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.00358	0.11	CbGbCtD
Dasatinib—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.00319	0.0978	CbGbCtD
Dasatinib—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.00312	0.0958	CbGbCtD
Dasatinib—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.00295	0.0905	CbGbCtD
Dasatinib—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00187	0.0574	CbGbCtD
Dasatinib—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00177	0.0542	CbGbCtD
Dasatinib—SRMS—respiratory system—chronic obstructive pulmonary disease	0.0014	0.0128	CbGeAlD
Dasatinib—TXK—respiratory system—chronic obstructive pulmonary disease	0.00139	0.0127	CbGeAlD
Dasatinib—SIK2—connective tissue—chronic obstructive pulmonary disease	0.00136	0.0124	CbGeAlD
Dasatinib—STAT5B—respiratory system—chronic obstructive pulmonary disease	0.0013	0.0119	CbGeAlD
Dasatinib—SRMS—connective tissue—chronic obstructive pulmonary disease	0.00123	0.0113	CbGeAlD
Dasatinib—SIK3—respiratory system—chronic obstructive pulmonary disease	0.00117	0.0107	CbGeAlD
Dasatinib—SRMS—bronchus—chronic obstructive pulmonary disease	0.00115	0.0106	CbGeAlD
Dasatinib—STAT5B—connective tissue—chronic obstructive pulmonary disease	0.00114	0.0105	CbGeAlD
Dasatinib—PTK6—bronchus—chronic obstructive pulmonary disease	0.00113	0.0103	CbGeAlD
Dasatinib—ZAK—respiratory system—chronic obstructive pulmonary disease	0.00109	0.00993	CbGeAlD
Dasatinib—MAP3K19—respiratory system—chronic obstructive pulmonary disease	0.00104	0.00952	CbGeAlD
Dasatinib—PTK6—trachea—chronic obstructive pulmonary disease	0.00102	0.00929	CbGeAlD
Dasatinib—LYN—connective tissue—chronic obstructive pulmonary disease	0.000931	0.00851	CbGeAlD
Dasatinib—LIMK2—respiratory system—chronic obstructive pulmonary disease	0.000913	0.00836	CbGeAlD
Dasatinib—BTK—connective tissue—chronic obstructive pulmonary disease	0.000912	0.00834	CbGeAlD
Dasatinib—ZAK—bronchus—chronic obstructive pulmonary disease	0.000894	0.00818	CbGeAlD
Dasatinib—CSK—respiratory system—chronic obstructive pulmonary disease	0.000879	0.00805	CbGeAlD
Dasatinib—BMPR1B—bronchus—chronic obstructive pulmonary disease	0.000857	0.00784	CbGeAlD
Dasatinib—BTK—bronchus—chronic obstructive pulmonary disease	0.000853	0.0078	CbGeAlD
Dasatinib—TESK1—connective tissue—chronic obstructive pulmonary disease	0.000845	0.00773	CbGeAlD
Dasatinib—SIK1—respiratory system—chronic obstructive pulmonary disease	0.000797	0.00729	CbGeAlD
Dasatinib—TESK1—bronchus—chronic obstructive pulmonary disease	0.00079	0.00723	CbGeAlD
Dasatinib—ERBB3—respiratory system—chronic obstructive pulmonary disease	0.000781	0.00715	CbGeAlD
Dasatinib—BMX—lung—chronic obstructive pulmonary disease	0.000778	0.00712	CbGeAlD
Dasatinib—STK36—bronchus—chronic obstructive pulmonary disease	0.000778	0.00711	CbGeAlD
Dasatinib—EPHB3—bronchus—chronic obstructive pulmonary disease	0.000778	0.00711	CbGeAlD
Dasatinib—CSK—connective tissue—chronic obstructive pulmonary disease	0.000774	0.00708	CbGeAlD
Dasatinib—LIMK2—bronchus—chronic obstructive pulmonary disease	0.000752	0.00688	CbGeAlD
Dasatinib—SRMS—lung—chronic obstructive pulmonary disease	0.000745	0.00681	CbGeAlD
Dasatinib—TXK—lung—chronic obstructive pulmonary disease	0.000737	0.00674	CbGeAlD
Dasatinib—PTK6—lung—chronic obstructive pulmonary disease	0.000729	0.00667	CbGeAlD
Dasatinib—MAPK14—respiratory system—chronic obstructive pulmonary disease	0.000728	0.00666	CbGeAlD
Dasatinib—FGR—respiratory system—chronic obstructive pulmonary disease	0.000725	0.00663	CbGeAlD
Dasatinib—CSK—bronchus—chronic obstructive pulmonary disease	0.000724	0.00662	CbGeAlD
Dasatinib—RIPK2—connective tissue—chronic obstructive pulmonary disease	0.000719	0.00657	CbGeAlD
Dasatinib—HCK—bronchus—chronic obstructive pulmonary disease	0.000715	0.00654	CbGeAlD
Dasatinib—TESK1—trachea—chronic obstructive pulmonary disease	0.000709	0.00649	CbGeAlD
Dasatinib—CSK—smooth muscle tissue—chronic obstructive pulmonary disease	0.000708	0.00648	CbGeAlD
Dasatinib—SIK1—connective tissue—chronic obstructive pulmonary disease	0.000702	0.00642	CbGeAlD
Dasatinib—FMO3—respiratory system—chronic obstructive pulmonary disease	0.0007	0.0064	CbGeAlD
Dasatinib—STK36—trachea—chronic obstructive pulmonary disease	0.000698	0.00639	CbGeAlD
Dasatinib—EPHB3—trachea—chronic obstructive pulmonary disease	0.000698	0.00639	CbGeAlD
Dasatinib—STAT5B—lung—chronic obstructive pulmonary disease	0.00069	0.00631	CbGeAlD
Dasatinib—EPHB4—respiratory system—chronic obstructive pulmonary disease	0.00069	0.00631	CbGeAlD
Dasatinib—ERBB3—connective tissue—chronic obstructive pulmonary disease	0.000688	0.00629	CbGeAlD
Dasatinib—JAK2—respiratory system—chronic obstructive pulmonary disease	0.000685	0.00626	CbGeAlD
Dasatinib—MAP3K2—connective tissue—chronic obstructive pulmonary disease	0.000681	0.00623	CbGeAlD
Dasatinib—EPHA2—respiratory system—chronic obstructive pulmonary disease	0.000677	0.00619	CbGeAlD
Dasatinib—FYN—respiratory system—chronic obstructive pulmonary disease	0.000675	0.00618	CbGeAlD
Dasatinib—LIMK2—trachea—chronic obstructive pulmonary disease	0.000675	0.00617	CbGeAlD
Dasatinib—RIPK2—bronchus—chronic obstructive pulmonary disease	0.000672	0.00615	CbGeAlD
Dasatinib—SIK1—bronchus—chronic obstructive pulmonary disease	0.000656	0.006	CbGeAlD
Dasatinib—CSK—trachea—chronic obstructive pulmonary disease	0.00065	0.00595	CbGeAlD
Dasatinib—EPHA4—bronchus—chronic obstructive pulmonary disease	0.000649	0.00594	CbGeAlD
Dasatinib—HCK—trachea—chronic obstructive pulmonary disease	0.000642	0.00587	CbGeAlD
Dasatinib—MAPK14—connective tissue—chronic obstructive pulmonary disease	0.00064	0.00586	CbGeAlD
Dasatinib—EPHA3—lung—chronic obstructive pulmonary disease	0.000638	0.00583	CbGeAlD
Dasatinib—SIK3—lung—chronic obstructive pulmonary disease	0.00062	0.00567	CbGeAlD
Dasatinib—YES1—respiratory system—chronic obstructive pulmonary disease	0.00061	0.00558	CbGeAlD
Dasatinib—EPHB4—connective tissue—chronic obstructive pulmonary disease	0.000607	0.00555	CbGeAlD
Dasatinib—RIPK2—trachea—chronic obstructive pulmonary disease	0.000603	0.00552	CbGeAlD
Dasatinib—JAK2—connective tissue—chronic obstructive pulmonary disease	0.000603	0.00551	CbGeAlD
Dasatinib—MAPK14—bronchus—chronic obstructive pulmonary disease	0.000599	0.00548	CbGeAlD
Dasatinib—PDGFRA—respiratory system—chronic obstructive pulmonary disease	0.000598	0.00547	CbGeAlD
Dasatinib—LCK—bronchus—chronic obstructive pulmonary disease	0.000596	0.00546	CbGeAlD
Dasatinib—FYN—connective tissue—chronic obstructive pulmonary disease	0.000595	0.00544	CbGeAlD
Dasatinib—SRC—respiratory system—chronic obstructive pulmonary disease	0.000586	0.00536	CbGeAlD
Dasatinib—MAPK14—smooth muscle tissue—chronic obstructive pulmonary disease	0.000586	0.00536	CbGeAlD
Dasatinib—EPHA4—trachea—chronic obstructive pulmonary disease	0.000583	0.00533	CbGeAlD
Dasatinib—ERBB3—trachea—chronic obstructive pulmonary disease	0.000577	0.00528	CbGeAlD
Dasatinib—ZAK—lung—chronic obstructive pulmonary disease	0.000577	0.00528	CbGeAlD
Dasatinib—FMO3—bronchus—chronic obstructive pulmonary disease	0.000576	0.00527	CbGeAlD
Dasatinib—EPHB4—bronchus—chronic obstructive pulmonary disease	0.000568	0.00519	CbGeAlD
Dasatinib—JAK2—bronchus—chronic obstructive pulmonary disease	0.000564	0.00516	CbGeAlD
Dasatinib—EPHA2—bronchus—chronic obstructive pulmonary disease	0.000557	0.00509	CbGeAlD
Dasatinib—FYN—bronchus—chronic obstructive pulmonary disease	0.000556	0.00509	CbGeAlD
Dasatinib—EPHB4—smooth muscle tissue—chronic obstructive pulmonary disease	0.000555	0.00508	CbGeAlD
Dasatinib—MAP3K19—lung—chronic obstructive pulmonary disease	0.000553	0.00506	CbGeAlD
Dasatinib—BMPR1B—lung—chronic obstructive pulmonary disease	0.000553	0.00506	CbGeAlD
Dasatinib—JAK2—smooth muscle tissue—chronic obstructive pulmonary disease	0.000551	0.00504	CbGeAlD
Dasatinib—BTK—lung—chronic obstructive pulmonary disease	0.00055	0.00503	CbGeAlD
Dasatinib—EPHB2—Diflorasone—Prednisone—chronic obstructive pulmonary disease	0.000549	0.241	CbGdCrCtD
Dasatinib—FYN—smooth muscle tissue—chronic obstructive pulmonary disease	0.000544	0.00498	CbGeAlD
Dasatinib—MAP4K5—bronchus—chronic obstructive pulmonary disease	0.000543	0.00497	CbGeAlD
Dasatinib—MAP3K3—bronchus—chronic obstructive pulmonary disease	0.000543	0.00497	CbGeAlD
Dasatinib—TNK2—lung—chronic obstructive pulmonary disease	0.000542	0.00496	CbGeAlD
Dasatinib—YES1—connective tissue—chronic obstructive pulmonary disease	0.000537	0.00491	CbGeAlD
Dasatinib—EPHB2—Diflorasone—Prednisolone—chronic obstructive pulmonary disease	0.000536	0.235	CbGdCrCtD
Dasatinib—LCK—trachea—chronic obstructive pulmonary disease	0.000535	0.0049	CbGeAlD
Dasatinib—MAP4K5—smooth muscle tissue—chronic obstructive pulmonary disease	0.000532	0.00486	CbGeAlD
Dasatinib—CSF1R—respiratory system—chronic obstructive pulmonary disease	0.000526	0.00482	CbGeAlD
Dasatinib—PDGFRA—connective tissue—chronic obstructive pulmonary disease	0.000526	0.00482	CbGeAlD
Dasatinib—EPHB6—bronchus—chronic obstructive pulmonary disease	0.000519	0.00475	CbGeAlD
Dasatinib—SRC—connective tissue—chronic obstructive pulmonary disease	0.000516	0.00472	CbGeAlD
Dasatinib—TESK1—lung—chronic obstructive pulmonary disease	0.00051	0.00466	CbGeAlD
Dasatinib—EPHB4—trachea—chronic obstructive pulmonary disease	0.00051	0.00466	CbGeAlD
Dasatinib—JAK2—trachea—chronic obstructive pulmonary disease	0.000506	0.00463	CbGeAlD
Dasatinib—YES1—bronchus—chronic obstructive pulmonary disease	0.000502	0.00459	CbGeAlD
Dasatinib—STK36—lung—chronic obstructive pulmonary disease	0.000502	0.00459	CbGeAlD
Dasatinib—EPHB3—lung—chronic obstructive pulmonary disease	0.000502	0.00459	CbGeAlD
Dasatinib—EPHA2—trachea—chronic obstructive pulmonary disease	0.0005	0.00457	CbGeAlD
Dasatinib—FYN—trachea—chronic obstructive pulmonary disease	0.000499	0.00457	CbGeAlD
Dasatinib—YES1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000491	0.00449	CbGeAlD
Dasatinib—MAP3K3—trachea—chronic obstructive pulmonary disease	0.000488	0.00446	CbGeAlD
Dasatinib—MAP4K5—trachea—chronic obstructive pulmonary disease	0.000488	0.00446	CbGeAlD
Dasatinib—LIMK2—lung—chronic obstructive pulmonary disease	0.000485	0.00444	CbGeAlD
Dasatinib—PDGFRA—smooth muscle tissue—chronic obstructive pulmonary disease	0.000482	0.00441	CbGeAlD
Dasatinib—KIT—respiratory system—chronic obstructive pulmonary disease	0.000478	0.00437	CbGeAlD
Dasatinib—SRC—smooth muscle tissue—chronic obstructive pulmonary disease	0.000472	0.00432	CbGeAlD
Dasatinib—STK35—lung—chronic obstructive pulmonary disease	0.00047	0.0043	CbGeAlD
Dasatinib—CSK—lung—chronic obstructive pulmonary disease	0.000467	0.00427	CbGeAlD
Dasatinib—PDGFRB—respiratory system—chronic obstructive pulmonary disease	0.000467	0.00427	CbGeAlD
Dasatinib—EPHB6—trachea—chronic obstructive pulmonary disease	0.000466	0.00426	CbGeAlD
Dasatinib—CSF1R—connective tissue—chronic obstructive pulmonary disease	0.000463	0.00424	CbGeAlD
Dasatinib—HCK—lung—chronic obstructive pulmonary disease	0.000461	0.00422	CbGeAlD
Dasatinib—ABL2—lung—chronic obstructive pulmonary disease	0.000458	0.00419	CbGeAlD
Dasatinib—YES1—trachea—chronic obstructive pulmonary disease	0.00045	0.00412	CbGeAlD
Dasatinib—MAP2K5—bronchus—chronic obstructive pulmonary disease	0.000444	0.00406	CbGeAlD
Dasatinib—PDGFRA—trachea—chronic obstructive pulmonary disease	0.000442	0.00404	CbGeAlD
Dasatinib—RIPK2—lung—chronic obstructive pulmonary disease	0.000433	0.00396	CbGeAlD
Dasatinib—CSF1R—bronchus—chronic obstructive pulmonary disease	0.000433	0.00396	CbGeAlD
Dasatinib—CSF1R—smooth muscle tissue—chronic obstructive pulmonary disease	0.000424	0.00388	CbGeAlD
Dasatinib—SIK1—lung—chronic obstructive pulmonary disease	0.000423	0.00387	CbGeAlD
Dasatinib—KIT—connective tissue—chronic obstructive pulmonary disease	0.000421	0.00385	CbGeAlD
Dasatinib—EPHA4—lung—chronic obstructive pulmonary disease	0.000419	0.00383	CbGeAlD
Dasatinib—ABL1—respiratory system—chronic obstructive pulmonary disease	0.000416	0.00381	CbGeAlD
Dasatinib—ERBB3—lung—chronic obstructive pulmonary disease	0.000415	0.0038	CbGeAlD
Dasatinib—PDGFRB—connective tissue—chronic obstructive pulmonary disease	0.000411	0.00376	CbGeAlD
Dasatinib—MAP3K2—lung—chronic obstructive pulmonary disease	0.000411	0.00376	CbGeAlD
Dasatinib—MAP2K5—trachea—chronic obstructive pulmonary disease	0.000399	0.00365	CbGeAlD
Dasatinib—KIT—bronchus—chronic obstructive pulmonary disease	0.000393	0.0036	CbGeAlD
Dasatinib—CSF1R—trachea—chronic obstructive pulmonary disease	0.000389	0.00356	CbGeAlD
Dasatinib—MAPK14—lung—chronic obstructive pulmonary disease	0.000386	0.00353	CbGeAlD
Dasatinib—KIT—smooth muscle tissue—chronic obstructive pulmonary disease	0.000385	0.00352	CbGeAlD
Dasatinib—FGR—lung—chronic obstructive pulmonary disease	0.000385	0.00352	CbGeAlD
Dasatinib—LCK—lung—chronic obstructive pulmonary disease	0.000385	0.00352	CbGeAlD
Dasatinib—PDGFRB—bronchus—chronic obstructive pulmonary disease	0.000384	0.00352	CbGeAlD
Dasatinib—PDGFRB—smooth muscle tissue—chronic obstructive pulmonary disease	0.000376	0.00344	CbGeAlD
Dasatinib—FMO3—lung—chronic obstructive pulmonary disease	0.000372	0.0034	CbGeAlD
Dasatinib—ABL1—connective tissue—chronic obstructive pulmonary disease	0.000366	0.00335	CbGeAlD
Dasatinib—EPHB4—lung—chronic obstructive pulmonary disease	0.000366	0.00335	CbGeAlD
Dasatinib—JAK2—lung—chronic obstructive pulmonary disease	0.000364	0.00333	CbGeAlD
Dasatinib—EPHA2—lung—chronic obstructive pulmonary disease	0.000359	0.00329	CbGeAlD
Dasatinib—FYN—lung—chronic obstructive pulmonary disease	0.000359	0.00328	CbGeAlD
Dasatinib—KIT—trachea—chronic obstructive pulmonary disease	0.000353	0.00323	CbGeAlD
Dasatinib—CYP1B1—respiratory system—chronic obstructive pulmonary disease	0.000352	0.00322	CbGeAlD
Dasatinib—MAP3K3—lung—chronic obstructive pulmonary disease	0.00035	0.00321	CbGeAlD
Dasatinib—MAP4K5—lung—chronic obstructive pulmonary disease	0.00035	0.00321	CbGeAlD
Dasatinib—PDGFRB—trachea—chronic obstructive pulmonary disease	0.000345	0.00316	CbGeAlD
Dasatinib—ABL1—bronchus—chronic obstructive pulmonary disease	0.000343	0.00313	CbGeAlD
Dasatinib—ABL1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000335	0.00307	CbGeAlD
Dasatinib—EPHB6—lung—chronic obstructive pulmonary disease	0.000335	0.00306	CbGeAlD
Dasatinib—YES1—lung—chronic obstructive pulmonary disease	0.000324	0.00296	CbGeAlD
Dasatinib—PDGFRA—lung—chronic obstructive pulmonary disease	0.000318	0.0029	CbGeAlD
Dasatinib—PKMYT1—Danazol—Prednisone—chronic obstructive pulmonary disease	0.000311	0.137	CbGdCrCtD
Dasatinib—SRC—lung—chronic obstructive pulmonary disease	0.000311	0.00285	CbGeAlD
Dasatinib—CYP1B1—connective tissue—chronic obstructive pulmonary disease	0.00031	0.00284	CbGeAlD
Dasatinib—ABL1—trachea—chronic obstructive pulmonary disease	0.000308	0.00281	CbGeAlD
Dasatinib—MAP2K5—lung—chronic obstructive pulmonary disease	0.000286	0.00262	CbGeAlD
Dasatinib—CYP1B1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000284	0.0026	CbGeAlD
Dasatinib—CSF1R—lung—chronic obstructive pulmonary disease	0.00028	0.00256	CbGeAlD
Dasatinib—KIT—lung—chronic obstructive pulmonary disease	0.000254	0.00232	CbGeAlD
Dasatinib—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000253	0.00231	CbGeAlD
Dasatinib—CYP1A1—respiratory system—chronic obstructive pulmonary disease	0.000249	0.00228	CbGeAlD
Dasatinib—PDGFRB—lung—chronic obstructive pulmonary disease	0.000248	0.00227	CbGeAlD
Dasatinib—CYP3A5—respiratory system—chronic obstructive pulmonary disease	0.000244	0.00223	CbGeAlD
Dasatinib—TESK1—Dexamethasone—Prednisone—chronic obstructive pulmonary disease	0.000223	0.0979	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Prednisone—chronic obstructive pulmonary disease	0.000223	0.0979	CbGdCrCtD
Dasatinib—ABL1—lung—chronic obstructive pulmonary disease	0.000221	0.00202	CbGeAlD
Dasatinib—TESK1—Dexamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000218	0.0956	CbGdCrCtD
Dasatinib—TESK1—Betamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000218	0.0956	CbGdCrCtD
Dasatinib—CYP1A1—bronchus—chronic obstructive pulmonary disease	0.000205	0.00188	CbGeAlD
Dasatinib—CYP1B1—lung—chronic obstructive pulmonary disease	0.000187	0.00171	CbGeAlD
Dasatinib—CYP1A1—trachea—chronic obstructive pulmonary disease	0.000184	0.00168	CbGeAlD
Dasatinib—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000171	0.00126	CcSEcCtD
Dasatinib—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000171	0.00126	CcSEcCtD
Dasatinib—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.000171	0.00126	CcSEcCtD
Dasatinib—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.00017	0.00126	CcSEcCtD
Dasatinib—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00017	0.00126	CcSEcCtD
Dasatinib—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.00126	CcSEcCtD
Dasatinib—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00017	0.00126	CcSEcCtD
Dasatinib—Oedema—Montelukast—chronic obstructive pulmonary disease	0.00017	0.00126	CcSEcCtD
Dasatinib—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.00125	CcSEcCtD
Dasatinib—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.00017	0.00125	CcSEcCtD
Dasatinib—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000169	0.00125	CcSEcCtD
Dasatinib—Infection—Montelukast—chronic obstructive pulmonary disease	0.000169	0.00125	CcSEcCtD
Dasatinib—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000169	0.00125	CcSEcCtD
Dasatinib—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000169	0.00125	CcSEcCtD
Dasatinib—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000169	0.00125	CcSEcCtD
Dasatinib—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000168	0.00124	CcSEcCtD
Dasatinib—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00123	CcSEcCtD
Dasatinib—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00123	CcSEcCtD
Dasatinib—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000167	0.00123	CcSEcCtD
Dasatinib—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000166	0.00123	CcSEcCtD
Dasatinib—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000165	0.00122	CcSEcCtD
Dasatinib—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.00121	CcSEcCtD
Dasatinib—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000163	0.0012	CcSEcCtD
Dasatinib—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.0012	CcSEcCtD
Dasatinib—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000162	0.0012	CcSEcCtD
Dasatinib—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.0012	CcSEcCtD
Dasatinib—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000161	0.00119	CcSEcCtD
Dasatinib—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.00119	CcSEcCtD
Dasatinib—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.00119	CcSEcCtD
Dasatinib—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000161	0.00119	CcSEcCtD
Dasatinib—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.00016	0.00118	CcSEcCtD
Dasatinib—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.00118	CcSEcCtD
Dasatinib—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000159	0.00117	CcSEcCtD
Dasatinib—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.00117	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000158	0.00117	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000158	0.00117	CcSEcCtD
Dasatinib—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000157	0.00116	CcSEcCtD
Dasatinib—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000157	0.00116	CcSEcCtD
Dasatinib—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000156	0.00115	CcSEcCtD
Dasatinib—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000156	0.00115	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000155	0.00114	CcSEcCtD
Dasatinib—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000155	0.00114	CcSEcCtD
Dasatinib—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000155	0.00114	CcSEcCtD
Dasatinib—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000154	0.00114	CcSEcCtD
Dasatinib—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000154	0.00114	CcSEcCtD
Dasatinib—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000154	0.00114	CcSEcCtD
Dasatinib—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000153	0.00113	CcSEcCtD
Dasatinib—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.00113	CcSEcCtD
Dasatinib—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000153	0.00113	CcSEcCtD
Dasatinib—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000153	0.00113	CcSEcCtD
Dasatinib—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000152	0.00112	CcSEcCtD
Dasatinib—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000151	0.00112	CcSEcCtD
Dasatinib—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000151	0.00111	CcSEcCtD
Dasatinib—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000151	0.00111	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00015	0.00111	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00015	0.00111	CcSEcCtD
Dasatinib—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.00015	0.00111	CcSEcCtD
Dasatinib—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00015	0.00111	CcSEcCtD
Dasatinib—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00015	0.00111	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000149	0.0011	CcSEcCtD
Dasatinib—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000149	0.0011	CcSEcCtD
Dasatinib—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000149	0.0011	CcSEcCtD
Dasatinib—Pain—Formoterol—chronic obstructive pulmonary disease	0.000149	0.0011	CcSEcCtD
Dasatinib—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000149	0.0011	CcSEcCtD
Dasatinib—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000148	0.0011	CcSEcCtD
Dasatinib—Amnesia—Prednisone—chronic obstructive pulmonary disease	0.000148	0.00109	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000147	0.00108	CcSEcCtD
Dasatinib—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000147	0.00108	CcSEcCtD
Dasatinib—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000146	0.00108	CcSEcCtD
Dasatinib—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000146	0.00108	CcSEcCtD
Dasatinib—Pain—Montelukast—chronic obstructive pulmonary disease	0.000145	0.00107	CcSEcCtD
Dasatinib—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000145	0.00107	CcSEcCtD
Dasatinib—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000145	0.00107	CcSEcCtD
Dasatinib—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000145	0.00107	CcSEcCtD
Dasatinib—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000145	0.00107	CcSEcCtD
Dasatinib—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000144	0.00107	CcSEcCtD
Dasatinib—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000144	0.00106	CcSEcCtD
Dasatinib—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000144	0.00106	CcSEcCtD
Dasatinib—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000143	0.00106	CcSEcCtD
Dasatinib—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000143	0.00106	CcSEcCtD
Dasatinib—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000143	0.00106	CcSEcCtD
Dasatinib—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000143	0.00106	CcSEcCtD
Dasatinib—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000143	0.00105	CcSEcCtD
Dasatinib—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000142	0.00105	CcSEcCtD
Dasatinib—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000142	0.00105	CcSEcCtD
Dasatinib—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000142	0.00105	CcSEcCtD
Dasatinib—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000142	0.00105	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000142	0.00105	CcSEcCtD
Dasatinib—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.00104	CcSEcCtD
Dasatinib—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.00014	0.00104	CcSEcCtD
Dasatinib—Pain—Salbutamol—chronic obstructive pulmonary disease	0.00014	0.00104	CcSEcCtD
Dasatinib—ABCG2—lung—chronic obstructive pulmonary disease	0.000139	0.00127	CbGeAlD
Dasatinib—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000139	0.00103	CcSEcCtD
Dasatinib—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000139	0.00103	CcSEcCtD
Dasatinib—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000138	0.00102	CcSEcCtD
Dasatinib—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000138	0.00102	CcSEcCtD
Dasatinib—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000137	0.00101	CcSEcCtD
Dasatinib—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000137	0.00101	CcSEcCtD
Dasatinib—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000137	0.00101	CcSEcCtD
Dasatinib—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000137	0.00101	CcSEcCtD
Dasatinib—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000137	0.00101	CcSEcCtD
Dasatinib—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000137	0.00101	CcSEcCtD
Dasatinib—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000136	0.001	CcSEcCtD
Dasatinib—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000136	0.001	CcSEcCtD
Dasatinib—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000136	0.001	CcSEcCtD
Dasatinib—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000135	0.000998	CcSEcCtD
Dasatinib—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000135	0.000998	CcSEcCtD
Dasatinib—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000135	0.000996	CcSEcCtD
Dasatinib—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000134	0.000993	CcSEcCtD
Dasatinib—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000134	0.000993	CcSEcCtD
Dasatinib—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000992	CcSEcCtD
Dasatinib—CYP1A2—lung—chronic obstructive pulmonary disease	0.000134	0.00123	CbGeAlD
Dasatinib—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000134	0.000991	CcSEcCtD
Dasatinib—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000133	0.000983	CcSEcCtD
Dasatinib—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000132	0.000978	CcSEcCtD
Dasatinib—CYP1A1—lung—chronic obstructive pulmonary disease	0.000132	0.00121	CbGeAlD
Dasatinib—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.000962	CcSEcCtD
Dasatinib—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.000958	CcSEcCtD
Dasatinib—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.000958	CcSEcCtD
Dasatinib—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000129	0.00118	CbGeAlD
Dasatinib—CYP3A5—lung—chronic obstructive pulmonary disease	0.000129	0.00118	CbGeAlD
Dasatinib—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000128	0.000945	CcSEcCtD
Dasatinib—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000128	0.000945	CcSEcCtD
Dasatinib—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000128	0.000944	CcSEcCtD
Dasatinib—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000128	0.000942	CcSEcCtD
Dasatinib—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000942	CcSEcCtD
Dasatinib—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000935	CcSEcCtD
Dasatinib—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000125	0.000926	CcSEcCtD
Dasatinib—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000125	0.000921	CcSEcCtD
Dasatinib—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000125	0.000921	CcSEcCtD
Dasatinib—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000123	0.000908	CcSEcCtD
Dasatinib—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000123	0.000908	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000906	CcSEcCtD
Dasatinib—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000906	CcSEcCtD
Dasatinib—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000122	0.000902	CcSEcCtD
Dasatinib—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000894	CcSEcCtD
Dasatinib—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.000893	CcSEcCtD
Dasatinib—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00012	0.000889	CcSEcCtD
Dasatinib—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000119	0.000878	CcSEcCtD
Dasatinib—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000119	0.000878	CcSEcCtD
Dasatinib—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000118	0.000874	CcSEcCtD
Dasatinib—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000871	CcSEcCtD
Dasatinib—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000118	0.000869	CcSEcCtD
Dasatinib—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000116	0.00086	CcSEcCtD
Dasatinib—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000116	0.000857	CcSEcCtD
Dasatinib—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000115	0.000851	CcSEcCtD
Dasatinib—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000115	0.000848	CcSEcCtD
Dasatinib—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000115	0.000848	CcSEcCtD
Dasatinib—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000112	0.000831	CcSEcCtD
Dasatinib—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000112	0.00083	CcSEcCtD
Dasatinib—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000112	0.000829	CcSEcCtD
Dasatinib—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00011	0.000816	CcSEcCtD
Dasatinib—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00011	0.000816	CcSEcCtD
Dasatinib—Rash—Formoterol—chronic obstructive pulmonary disease	0.00011	0.000809	CcSEcCtD
Dasatinib—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00011	0.000809	CcSEcCtD
Dasatinib—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000109	0.000808	CcSEcCtD
Dasatinib—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000109	0.000808	CcSEcCtD
Dasatinib—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000808	CcSEcCtD
Dasatinib—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000109	0.000804	CcSEcCtD
Dasatinib—Headache—Formoterol—chronic obstructive pulmonary disease	0.000109	0.000804	CcSEcCtD
Dasatinib—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000803	CcSEcCtD
Dasatinib—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000109	0.000802	CcSEcCtD
Dasatinib—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000108	0.000801	CcSEcCtD
Dasatinib—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000108	0.000799	CcSEcCtD
Dasatinib—Rash—Montelukast—chronic obstructive pulmonary disease	0.000107	0.000792	CcSEcCtD
Dasatinib—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000107	0.000792	CcSEcCtD
Dasatinib—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000107	0.00079	CcSEcCtD
Dasatinib—Headache—Montelukast—chronic obstructive pulmonary disease	0.000107	0.000787	CcSEcCtD
Dasatinib—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000106	0.00078	CcSEcCtD
Dasatinib—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000776	CcSEcCtD
Dasatinib—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000776	CcSEcCtD
Dasatinib—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000104	0.00077	CcSEcCtD
Dasatinib—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000104	0.000768	CcSEcCtD
Dasatinib—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000104	0.000765	CcSEcCtD
Dasatinib—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000103	0.000764	CcSEcCtD
Dasatinib—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.000763	CcSEcCtD
Dasatinib—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000103	0.000763	CcSEcCtD
Dasatinib—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000103	0.000762	CcSEcCtD
Dasatinib—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000103	0.000762	CcSEcCtD
Dasatinib—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000103	0.000759	CcSEcCtD
Dasatinib—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.000748	CcSEcCtD
Dasatinib—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000101	0.000746	CcSEcCtD
Dasatinib—Convulsion—Prednisolone—chronic obstructive pulmonary disease	9.99e-05	0.000738	CcSEcCtD
Dasatinib—Hypertension—Prednisolone—chronic obstructive pulmonary disease	9.95e-05	0.000735	CcSEcCtD
Dasatinib—Nausea—Salbutamol—chronic obstructive pulmonary disease	9.74e-05	0.00072	CcSEcCtD
Dasatinib—Discomfort—Prednisolone—chronic obstructive pulmonary disease	9.69e-05	0.000716	CcSEcCtD
Dasatinib—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	9.67e-05	0.000714	CcSEcCtD
Dasatinib—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	9.62e-05	0.000711	CcSEcCtD
Dasatinib—ABCB1—trachea—chronic obstructive pulmonary disease	9.56e-05	0.000875	CbGeAlD
Dasatinib—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	9.45e-05	0.000698	CcSEcCtD
Dasatinib—Oedema—Prednisolone—chronic obstructive pulmonary disease	9.41e-05	0.000695	CcSEcCtD
Dasatinib—Shock—Prednisolone—chronic obstructive pulmonary disease	9.25e-05	0.000684	CcSEcCtD
Dasatinib—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	9.18e-05	0.000678	CcSEcCtD
Dasatinib—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	9.09e-05	0.000672	CcSEcCtD
Dasatinib—Eye disorder—Prednisone—chronic obstructive pulmonary disease	8.99e-05	0.000664	CcSEcCtD
Dasatinib—Flushing—Prednisone—chronic obstructive pulmonary disease	8.93e-05	0.00066	CcSEcCtD
Dasatinib—Angiopathy—Prednisone—chronic obstructive pulmonary disease	8.73e-05	0.000645	CcSEcCtD
Dasatinib—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	8.69e-05	0.000642	CcSEcCtD
Dasatinib—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	8.59e-05	0.000635	CcSEcCtD
Dasatinib—Insomnia—Prednisolone—chronic obstructive pulmonary disease	8.51e-05	0.000628	CcSEcCtD
Dasatinib—Alopecia—Prednisone—chronic obstructive pulmonary disease	8.5e-05	0.000628	CcSEcCtD
Dasatinib—Mental disorder—Prednisone—chronic obstructive pulmonary disease	8.43e-05	0.000623	CcSEcCtD
Dasatinib—Erythema—Prednisone—chronic obstructive pulmonary disease	8.37e-05	0.000619	CcSEcCtD
Dasatinib—Malnutrition—Prednisone—chronic obstructive pulmonary disease	8.37e-05	0.000619	CcSEcCtD
Dasatinib—Pain—Prednisolone—chronic obstructive pulmonary disease	8.04e-05	0.000594	CcSEcCtD
Dasatinib—Vision blurred—Prednisone—chronic obstructive pulmonary disease	7.89e-05	0.000583	CcSEcCtD
Dasatinib—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	7.77e-05	0.000574	CcSEcCtD
Dasatinib—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	7.75e-05	0.000573	CcSEcCtD
Dasatinib—Anaemia—Prednisone—chronic obstructive pulmonary disease	7.74e-05	0.000572	CcSEcCtD
Dasatinib—Malaise—Prednisone—chronic obstructive pulmonary disease	7.55e-05	0.000558	CcSEcCtD
Dasatinib—Vertigo—Prednisone—chronic obstructive pulmonary disease	7.52e-05	0.000556	CcSEcCtD
Dasatinib—Syncope—Prednisone—chronic obstructive pulmonary disease	7.51e-05	0.000555	CcSEcCtD
Dasatinib—Urticaria—Prednisolone—chronic obstructive pulmonary disease	7.47e-05	0.000552	CcSEcCtD
Dasatinib—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	7.36e-05	0.000544	CcSEcCtD
Dasatinib—Convulsion—Prednisone—chronic obstructive pulmonary disease	7.26e-05	0.000536	CcSEcCtD
Dasatinib—Hypertension—Prednisone—chronic obstructive pulmonary disease	7.23e-05	0.000534	CcSEcCtD
Dasatinib—Myalgia—Prednisone—chronic obstructive pulmonary disease	7.13e-05	0.000527	CcSEcCtD
Dasatinib—Arthralgia—Prednisone—chronic obstructive pulmonary disease	7.13e-05	0.000527	CcSEcCtD
Dasatinib—Anxiety—Prednisone—chronic obstructive pulmonary disease	7.11e-05	0.000525	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	7.08e-05	0.000523	CcSEcCtD
Dasatinib—Discomfort—Prednisone—chronic obstructive pulmonary disease	7.04e-05	0.00052	CcSEcCtD
Dasatinib—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	6.93e-05	0.000512	CcSEcCtD
Dasatinib—ABCB1—lung—chronic obstructive pulmonary disease	6.87e-05	0.000629	CbGeAlD
Dasatinib—Oedema—Prednisone—chronic obstructive pulmonary disease	6.84e-05	0.000505	CcSEcCtD
Dasatinib—Infection—Prednisone—chronic obstructive pulmonary disease	6.79e-05	0.000502	CcSEcCtD
Dasatinib—Shock—Prednisone—chronic obstructive pulmonary disease	6.72e-05	0.000497	CcSEcCtD
Dasatinib—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	6.7e-05	0.000495	CcSEcCtD
Dasatinib—Tachycardia—Prednisone—chronic obstructive pulmonary disease	6.67e-05	0.000493	CcSEcCtD
Dasatinib—Skin disorder—Prednisone—chronic obstructive pulmonary disease	6.64e-05	0.00049	CcSEcCtD
Dasatinib—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	6.61e-05	0.000488	CcSEcCtD
Dasatinib—Anorexia—Prednisone—chronic obstructive pulmonary disease	6.52e-05	0.000481	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	6.23e-05	0.00046	CcSEcCtD
Dasatinib—Dizziness—Prednisolone—chronic obstructive pulmonary disease	6.22e-05	0.000459	CcSEcCtD
Dasatinib—Insomnia—Prednisone—chronic obstructive pulmonary disease	6.18e-05	0.000457	CcSEcCtD
Dasatinib—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	6.02e-05	0.000444	CcSEcCtD
Dasatinib—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	5.94e-05	0.000439	CcSEcCtD
Dasatinib—Rash—Prednisolone—chronic obstructive pulmonary disease	5.93e-05	0.000438	CcSEcCtD
Dasatinib—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	5.93e-05	0.000438	CcSEcCtD
Dasatinib—Fatigue—Prednisone—chronic obstructive pulmonary disease	5.89e-05	0.000435	CcSEcCtD
Dasatinib—Headache—Prednisolone—chronic obstructive pulmonary disease	5.89e-05	0.000435	CcSEcCtD
Dasatinib—Constipation—Prednisone—chronic obstructive pulmonary disease	5.84e-05	0.000432	CcSEcCtD
Dasatinib—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	5.63e-05	0.000416	CcSEcCtD
Dasatinib—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	5.59e-05	0.000413	CcSEcCtD
Dasatinib—Nausea—Prednisolone—chronic obstructive pulmonary disease	5.59e-05	0.000413	CcSEcCtD
Dasatinib—Urticaria—Prednisone—chronic obstructive pulmonary disease	5.43e-05	0.000401	CcSEcCtD
Dasatinib—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	5.4e-05	0.000399	CcSEcCtD
Dasatinib—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	5.4e-05	0.000399	CcSEcCtD
Dasatinib—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	5.04e-05	0.000372	CcSEcCtD
Dasatinib—Asthenia—Prednisone—chronic obstructive pulmonary disease	4.9e-05	0.000362	CcSEcCtD
Dasatinib—Pruritus—Prednisone—chronic obstructive pulmonary disease	4.84e-05	0.000357	CcSEcCtD
Dasatinib—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	4.68e-05	0.000345	CcSEcCtD
Dasatinib—Dizziness—Prednisone—chronic obstructive pulmonary disease	4.52e-05	0.000334	CcSEcCtD
Dasatinib—Vomiting—Prednisone—chronic obstructive pulmonary disease	4.35e-05	0.000321	CcSEcCtD
Dasatinib—Rash—Prednisone—chronic obstructive pulmonary disease	4.31e-05	0.000318	CcSEcCtD
Dasatinib—Dermatitis—Prednisone—chronic obstructive pulmonary disease	4.31e-05	0.000318	CcSEcCtD
Dasatinib—Headache—Prednisone—chronic obstructive pulmonary disease	4.28e-05	0.000316	CcSEcCtD
Dasatinib—Nausea—Prednisone—chronic obstructive pulmonary disease	4.06e-05	0.0003	CcSEcCtD
Dasatinib—LCK—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	4.01e-06	2.75e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—IL6—chronic obstructive pulmonary disease	4e-06	2.74e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—TNF—chronic obstructive pulmonary disease	3.99e-06	2.73e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.98e-06	2.73e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—EGFR—chronic obstructive pulmonary disease	3.98e-06	2.73e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL1B—chronic obstructive pulmonary disease	3.98e-06	2.72e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.98e-06	2.72e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.97e-06	2.72e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—NOS3—chronic obstructive pulmonary disease	3.95e-06	2.71e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—IL6—chronic obstructive pulmonary disease	3.95e-06	2.71e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.95e-06	2.71e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	3.94e-06	2.7e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—IL6—chronic obstructive pulmonary disease	3.91e-06	2.68e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—IL6—chronic obstructive pulmonary disease	3.9e-06	2.67e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—chronic obstructive pulmonary disease	3.89e-06	2.67e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL1B—chronic obstructive pulmonary disease	3.89e-06	2.67e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.89e-06	2.66e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL1B—chronic obstructive pulmonary disease	3.88e-06	2.66e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—IL6—chronic obstructive pulmonary disease	3.87e-06	2.65e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.87e-06	2.65e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.86e-06	2.64e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—IL6—chronic obstructive pulmonary disease	3.85e-06	2.64e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL1B—chronic obstructive pulmonary disease	3.83e-06	2.63e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	3.82e-06	2.62e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—NOS2—chronic obstructive pulmonary disease	3.81e-06	2.61e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—IL6—chronic obstructive pulmonary disease	3.8e-06	2.6e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—IL6—chronic obstructive pulmonary disease	3.79e-06	2.6e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.76e-06	2.58e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.74e-06	2.56e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.74e-06	2.56e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.71e-06	2.54e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—IL6—chronic obstructive pulmonary disease	3.71e-06	2.54e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—EGFR—chronic obstructive pulmonary disease	3.7e-06	2.53e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.7e-06	2.53e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.69e-06	2.53e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL1B—chronic obstructive pulmonary disease	3.69e-06	2.53e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—IL6—chronic obstructive pulmonary disease	3.66e-06	2.51e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL1B—chronic obstructive pulmonary disease	3.64e-06	2.5e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—SERPINE1—chronic obstructive pulmonary disease	3.63e-06	2.48e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.63e-06	2.48e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.62e-06	2.48e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.55e-06	2.43e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—EGFR—chronic obstructive pulmonary disease	3.55e-06	2.43e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	3.55e-06	2.43e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.54e-06	2.43e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.53e-06	2.42e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.52e-06	2.41e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.52e-06	2.41e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.51e-06	2.41e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.5e-06	2.4e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	3.49e-06	2.39e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IL6—chronic obstructive pulmonary disease	3.48e-06	2.39e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.48e-06	2.39e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—NOS3—chronic obstructive pulmonary disease	3.46e-06	2.37e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—chronic obstructive pulmonary disease	3.45e-06	2.36e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.42e-06	2.34e-05	CbGpPWpGaD
Dasatinib—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	3.39e-06	2.32e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.39e-06	2.32e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.38e-06	2.31e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—EGFR—chronic obstructive pulmonary disease	3.36e-06	2.3e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.36e-06	2.3e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.35e-06	2.3e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—TGFB1—chronic obstructive pulmonary disease	3.35e-06	2.29e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.32e-06	2.28e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.31e-06	2.27e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—EGFR—chronic obstructive pulmonary disease	3.28e-06	2.25e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.27e-06	2.24e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.26e-06	2.23e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.24e-06	2.22e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—ALB—chronic obstructive pulmonary disease	3.23e-06	2.21e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—IL6—chronic obstructive pulmonary disease	3.22e-06	2.2e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—IL6—chronic obstructive pulmonary disease	3.22e-06	2.2e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.22e-06	2.2e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—SERPINE1—chronic obstructive pulmonary disease	3.21e-06	2.2e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—IL6—chronic obstructive pulmonary disease	3.21e-06	2.2e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.2e-06	2.19e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL1B—chronic obstructive pulmonary disease	3.19e-06	2.19e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.18e-06	2.18e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—TGFB1—chronic obstructive pulmonary disease	3.17e-06	2.17e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.17e-06	2.17e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.14e-06	2.15e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—EGFR—chronic obstructive pulmonary disease	3.11e-06	2.13e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.1e-06	2.12e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.1e-06	2.12e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.1e-06	2.12e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.09e-06	2.12e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.09e-06	2.12e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.09e-06	2.11e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.08e-06	2.11e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—NOS3—chronic obstructive pulmonary disease	3.07e-06	2.1e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—IL6—chronic obstructive pulmonary disease	3.06e-06	2.09e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	3.05e-06	2.09e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.05e-06	2.09e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.04e-06	2.08e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.04e-06	2.08e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—EGFR—chronic obstructive pulmonary disease	3.03e-06	2.08e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.02e-06	2.07e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.99e-06	2.05e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.98e-06	2.04e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—EGFR—chronic obstructive pulmonary disease	2.97e-06	2.03e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.96e-06	2.03e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—EGFR—chronic obstructive pulmonary disease	2.95e-06	2.02e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.94e-06	2.01e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—ALB—chronic obstructive pulmonary disease	2.94e-06	2.01e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.93e-06	2.01e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—EGFR—chronic obstructive pulmonary disease	2.92e-06	2e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.91e-06	2e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.9e-06	1.99e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.87e-06	1.96e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.86e-06	1.96e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—TGFB1—chronic obstructive pulmonary disease	2.85e-06	1.95e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.85e-06	1.95e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.84e-06	1.95e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—IL6—chronic obstructive pulmonary disease	2.84e-06	1.95e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL1B—chronic obstructive pulmonary disease	2.83e-06	1.94e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EGFR—chronic obstructive pulmonary disease	2.81e-06	1.93e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.81e-06	1.92e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.8e-06	1.92e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EGFR—chronic obstructive pulmonary disease	2.8e-06	1.92e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.79e-06	1.91e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	2.79e-06	1.91e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EGFR—chronic obstructive pulmonary disease	2.78e-06	1.9e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.77e-06	1.9e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—TGFB1—chronic obstructive pulmonary disease	2.75e-06	1.88e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL6—chronic obstructive pulmonary disease	2.73e-06	1.87e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—EGFR—chronic obstructive pulmonary disease	2.7e-06	1.85e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.69e-06	1.84e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.68e-06	1.84e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.68e-06	1.84e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.64e-06	1.81e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.62e-06	1.8e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.62e-06	1.8e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—TGFB1—chronic obstructive pulmonary disease	2.61e-06	1.79e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL6—chronic obstructive pulmonary disease	2.58e-06	1.77e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.58e-06	1.77e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.57e-06	1.76e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—EGFR—chronic obstructive pulmonary disease	2.56e-06	1.76e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.55e-06	1.75e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.55e-06	1.75e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.55e-06	1.75e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.54e-06	1.74e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—IL6—chronic obstructive pulmonary disease	2.52e-06	1.73e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.49e-06	1.7e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.46e-06	1.69e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.46e-06	1.69e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.46e-06	1.68e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—chronic obstructive pulmonary disease	2.43e-06	1.67e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.42e-06	1.66e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.42e-06	1.66e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.42e-06	1.66e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—IL6—chronic obstructive pulmonary disease	2.39e-06	1.64e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.38e-06	1.63e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.37e-06	1.63e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	2.36e-06	1.61e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.34e-06	1.61e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.34e-06	1.6e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.34e-06	1.6e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.34e-06	1.6e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.34e-06	1.6e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL6—chronic obstructive pulmonary disease	2.33e-06	1.6e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.3e-06	1.57e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—TGFB1—chronic obstructive pulmonary disease	2.29e-06	1.57e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL6—chronic obstructive pulmonary disease	2.28e-06	1.56e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL6—chronic obstructive pulmonary disease	2.27e-06	1.55e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.25e-06	1.54e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.25e-06	1.54e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.25e-06	1.54e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—chronic obstructive pulmonary disease	2.25e-06	1.54e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL6—chronic obstructive pulmonary disease	2.24e-06	1.54e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.22e-06	1.52e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.22e-06	1.52e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.18e-06	1.49e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.17e-06	1.49e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—chronic obstructive pulmonary disease	2.16e-06	1.48e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.16e-06	1.48e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—chronic obstructive pulmonary disease	2.15e-06	1.47e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.15e-06	1.47e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—chronic obstructive pulmonary disease	2.15e-06	1.47e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	2.15e-06	1.47e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.15e-06	1.47e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.14e-06	1.47e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—chronic obstructive pulmonary disease	2.13e-06	1.46e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.13e-06	1.46e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.11e-06	1.45e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	2.1e-06	1.44e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.1e-06	1.44e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—chronic obstructive pulmonary disease	2.07e-06	1.42e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFB1—chronic obstructive pulmonary disease	2.03e-06	1.39e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.02e-06	1.38e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	2.01e-06	1.38e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2e-06	1.37e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.99e-06	1.37e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ALB—chronic obstructive pulmonary disease	1.99e-06	1.36e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—chronic obstructive pulmonary disease	1.99e-06	1.36e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.98e-06	1.36e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.98e-06	1.35e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—chronic obstructive pulmonary disease	1.97e-06	1.35e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.97e-06	1.35e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.96e-06	1.34e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.96e-06	1.34e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.95e-06	1.33e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.93e-06	1.32e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.93e-06	1.32e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.92e-06	1.31e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.9e-06	1.3e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.9e-06	1.3e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.89e-06	1.29e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—chronic obstructive pulmonary disease	1.87e-06	1.28e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.86e-06	1.28e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.85e-06	1.27e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.83e-06	1.25e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.83e-06	1.25e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.82e-06	1.25e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.8e-06	1.23e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.77e-06	1.21e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.75e-06	1.2e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—chronic obstructive pulmonary disease	1.73e-06	1.18e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.72e-06	1.18e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.67e-06	1.14e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—chronic obstructive pulmonary disease	1.65e-06	1.13e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.65e-06	1.13e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.64e-06	1.13e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.63e-06	1.12e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.61e-06	1.1e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.6e-06	1.1e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	1.59e-06	1.09e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.59e-06	1.09e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.57e-06	1.08e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.55e-06	1.06e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—chronic obstructive pulmonary disease	1.53e-06	1.05e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.53e-06	1.05e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.52e-06	1.04e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.52e-06	1.04e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.51e-06	1.03e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.51e-06	1.03e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.47e-06	1.01e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.45e-06	9.94e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.44e-06	9.86e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.42e-06	9.73e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.4e-06	9.57e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.39e-06	9.54e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.38e-06	9.45e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.32e-06	9.04e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	1.27e-06	8.68e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	1.21e-06	8.31e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.21e-06	8.28e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.17e-06	8.01e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.07e-06	7.33e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	9.78e-07	6.7e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	9.36e-07	6.41e-06	CbGpPWpGaD
